166 related articles for article (PubMed ID: 33723329)
21. New insight on the correlation of metabolic status on
Wang Y; Zhao N; Wu Z; Pan N; Shen X; Liu T; Wei F; You J; Xu W; Ren X
Eur J Nucl Med Mol Imaging; 2020 May; 47(5):1127-1136. PubMed ID: 31502013
[TBL] [Abstract][Full Text] [Related]
22. Development and validation of an
Wang H; Zhao S; Li L; Tian R
Eur Radiol; 2020 Oct; 30(10):5578-5587. PubMed ID: 32435928
[TBL] [Abstract][Full Text] [Related]
23. Diagnostic and prognostic value of pretreatment PET/CT in extranodal natural killer/T-cell lymphoma: a retrospective multicenter study.
Yu M; Chen Z; Wang Z; Fang X; Li X; Ye H; Lin T; Huang H
J Cancer Res Clin Oncol; 2023 Sep; 149(11):8863-8875. PubMed ID: 37148293
[TBL] [Abstract][Full Text] [Related]
24. [Prognostic value of pretreatment (18)F-FDG PET-CT for patients with advanced diffuse large B-cell lymphoma].
Ding CY; Guo Z; Sun J; Yang WP; Li TR
Zhonghua Zhong Liu Za Zhi; 2018 Jul; 40(7):528-533. PubMed ID: 30060362
[No Abstract] [Full Text] [Related]
25.
Li Y; Wu X; Huang Y; Bian D; Jiang L
Ann Nucl Med; 2020 May; 34(5):314-321. PubMed ID: 32088884
[TBL] [Abstract][Full Text] [Related]
26. Prognostic role of pretreatment 18F-FDG PET/CT in primary brain lymphoma.
Albano D; Bertoli M; Battistotti M; Rodella C; Statuto M; Giubbini R; Bertagna F
Ann Nucl Med; 2018 Oct; 32(8):532-541. PubMed ID: 29982990
[TBL] [Abstract][Full Text] [Related]
27. [Correlation of ¹⁸F-FDG uptake with tumor-proliferating antigen Ki-67 expression in aggressive lymphoma].
Liang Y; Wu N; Fang Y; Huang WT; Zhang H; Zheng R; Zhang WJ; Liu Y; Li XM
Zhonghua Zhong Liu Za Zhi; 2013 May; 35(5):356-60. PubMed ID: 24054012
[TBL] [Abstract][Full Text] [Related]
28. Prognostic Value of Pretreatment Metabolic Tumor Volume and Total Lesion Glycolysis Using 18F-FDG PET/CT in Patients With Metastatic Renal Cell Carcinoma Treated With Anti-Vascular Endothelial Growth Factor-Targeted Agents.
Hwang SH; Cho A; Yun M; Choi YD; Rha SY; Kang WJ
Clin Nucl Med; 2017 May; 42(5):e235-e241. PubMed ID: 28288043
[TBL] [Abstract][Full Text] [Related]
29.
Wu X; Huang Y; Li Y; Wang Q; Wang H; Jiang L
Ann Nucl Med; 2019 Sep; 33(9):647-656. PubMed ID: 31165974
[TBL] [Abstract][Full Text] [Related]
30. [(18)F-FDG PET/CT for extranodular natural killer/T-cell lymphoma nasal type: imaging findings and clinical value].
Song JH; Qiao WL; Chen X; Liu CC; Xing Y; Wang TS; Zhao JH
Nan Fang Yi Ke Da Xue Xue Bao; 2016 Aug; 36(8):1123-8. PubMed ID: 27578584
[TBL] [Abstract][Full Text] [Related]
31. Immune subtyping of extranodal NK/T-cell lymphoma: a new biomarker and an immune shift during disease progression.
Cho J; Kim SJ; Park WY; Kim J; Woo J; Kim G; Yoon SE; Ko YH; Kim WS
Mod Pathol; 2020 Apr; 33(4):603-615. PubMed ID: 31653980
[TBL] [Abstract][Full Text] [Related]
32. Extranodal NK/T-Cell Lymphoma With Widespread Cutaneous and Subcutaneous Involvement on 18 F-FDG PET/CT.
Filizoglu N; Ozguven S; Ones T; Turoglu HT; Erdil TY
Clin Nucl Med; 2022 Oct; 47(10):e630-e631. PubMed ID: 35383610
[TBL] [Abstract][Full Text] [Related]
33. 18F-FDG PET/CT and circulating tumor cells in treatment-naive patients with non-small-cell lung cancer.
Zhang F; Wu X; Zhu J; Huang Y; Song X; Jiang L
Eur J Nucl Med Mol Imaging; 2021 Sep; 48(10):3250-3259. PubMed ID: 33630146
[TBL] [Abstract][Full Text] [Related]
34. Utility of baseline, interim and end-of-treatment
Chang Y; Fu X; Sun Z; Xie X; Wang R; Li Z; Zhang X; Sheng G; Zhang M
Sci Rep; 2017 Jan; 7():41057. PubMed ID: 28117395
[TBL] [Abstract][Full Text] [Related]
35. Beyond the lymph nodes: FDG-PET/CT in primary extranodal lymphoma.
Sin KM; Ho SK; Wong BY; Gill H; Khong PL; Lee EY
Clin Imaging; 2017; 42():25-33. PubMed ID: 27875758
[TBL] [Abstract][Full Text] [Related]
36. Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancer.
Liao S; Penney BC; Wroblewski K; Zhang H; Simon CA; Kampalath R; Shih MC; Shimada N; Chen S; Salgia R; Appelbaum DE; Suzuki K; Chen CT; Pu Y
Eur J Nucl Med Mol Imaging; 2012 Jan; 39(1):27-38. PubMed ID: 21946983
[TBL] [Abstract][Full Text] [Related]
37. Prognostic Value of Metabolic and Volumetric Parameters of Preoperative FDG-PET/CT in Patients With Resectable Pancreatic Cancer.
Im HJ; Oo S; Jung W; Jang JY; Kim SW; Cheon GJ; Kang KW; Chung JK; Kim EE; Lee DS
Medicine (Baltimore); 2016 May; 95(19):e3686. PubMed ID: 27175707
[TBL] [Abstract][Full Text] [Related]
38. Nasal-Type Extranodal Natural Killer/T-Cell Lymphoma Recurrence at Penile Glans Masquerading Urinary Contamination on 18 F-FDG PET/CT.
Zhang Y; Yu L; Wang R; Su M
Clin Nucl Med; 2023 Sep; 48(9):812-814. PubMed ID: 37418289
[TBL] [Abstract][Full Text] [Related]
39. Prognostic role of baseline
Albano D; Bosio G; Camoni L; Farina M; Re A; Tucci A; Giubbini R; Bertagna F
Hematol Oncol; 2019 Feb; 37(1):39-46. PubMed ID: 30299563
[TBL] [Abstract][Full Text] [Related]
40. Prognostic significance of standardized uptake value and metabolic tumour volume on ¹⁸F-FDG PET/CT in oropharyngeal squamous cell carcinoma.
Kim JW; Oh JS; Roh JL; Kim JS; Choi SH; Nam SY; Kim SY
Eur J Nucl Med Mol Imaging; 2015 Aug; 42(9):1353-61. PubMed ID: 26067088
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
